Dataset Information

Receptor recharge time drastically reduces the number of captured particles.

ABSTRACT: Many diverse biological systems are described by randomly moving particles that can be captured by traps in their environment. Examples include neurotransmitters diffusing in the synaptic cleft before binding to receptors and prey roaming an environment before capture by predators. In most cases, the traps cannot capture particles continuously. Rather, each trap must wait a transitory "recharge" time after capturing a particle before additional captures. This recharge time is often overlooked. In the case of instant recharge, the average number of particles captured before they escape grows linearly in the total number of particles. In stark contrast, we prove that for any nonzero recharge time, the average number of captured particles grows at most logarithmically in the total particle number. This is a fundamental effect of recharge, as it holds under very general assumptions on particle motion and spatial domain. Furthermore, we characterize the parameter regime in which a given recharge time will dramatically affect a system, allowing researchers to easily verify if they need to account for recharge in their specific system. Finally, we consider a few examples, including a neural system in which recharge reduces neurotransmitter bindings by several orders of magnitude.

SUBMITTER: Handy G

PROVIDER: S-EPMC5849338 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Receptor recharge time drastically reduces the number of captured particles.

Handy Gregory G Lawley Sean D SD Borisyuk Alla A

PLoS computational biology 20180301 3

Many diverse biological systems are described by randomly moving particles that can be captured by traps in their environment. Examples include neurotransmitters diffusing in the synaptic cleft before binding to receptors and prey roaming an environment before capture by predators. In most cases, the traps cannot capture particles continuously. Rather, each trap must wait a transitory "recharge" time after capturing a particle before additional captures. This recharge time is often overlooked. I ...[more]

PMID: 29494590

Similar Datasets

Project description:Silicosis is a lethal fibro-granulomatous pulmonary disease highly prevalent in developing countries, for which no proper therapy is available. Among a small series of N-acylhydrazones, the safrole-derived compound LASSBio-897 (3-thienylidene-3, 4-methylenedioxybenzoylhydrazide) raised interest due to its ability to bind to the adenosine A2A receptor. Here, we evaluated the anti-inflammatory and anti-fibrotic potential of LASSBio-897, exploring translation to a mouse model of silicosis and the A2A receptor as a site of action. Pulmonary mechanics, inflammatory, and fibrotic changes were assessed 28 days after intranasal instillation of silica particles in Swiss-Webster mice. Glosensor cAMP HEK293G cells, CHO cells stably expressing human adenosine receptors and ligand binding assay were used to evaluate the pharmacological properties of LASSBio-897 in vitro. Molecular docking studies of LASSBio-897 were performed using the genetic algorithm software GOLD 5.2. We found that the interventional treatment with the A2A receptor agonist CGS 21680 reversed silica particle-induced airway hyper-reactivity as revealed by increased responses of airway resistance and lung elastance following aerosolized methacholine. LASSBio-897 (2 and 5 mg/kg, oral) similarly reversed pivotal lung pathological features of silicosis in this model, reducing levels of airway resistance and lung elastance, granuloma formation and collagen deposition. In competition assays, LASSBio-897 decreased the binding of the selective A2A receptor agonist [3H]-CGS21680 (IC50 = 9.3 ?M). LASSBio-897 (50 ?M) induced modest cAMP production in HEK293G cells, but it clearly synergized the cAMP production by adenosine in a mechanism sensitive to the A2A antagonist SCH 58261. This synergism was also seen in CHO cells expressing the A2A, but not those expressing A2B, A1 or A3 receptors. Based on the evidence that LASSBio-897 binds to A2A receptor, molecular docking studies were performed using the A2A receptor crystal structure and revealed possible binding modes of LASSBio-897 at the orthosteric and allosteric sites. These findings highlight LASSBio-897 as a lead compound in drug development for silicosis, emphasizing the role of the A2A receptor as its putative site of action.

Dataset Information

Receptor recharge time drastically reduces the number of captured particles.

Publications

Receptor recharge time drastically reduces the number of captured particles.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets